Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)

Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead to difficulties walking, talking, eating, epilepsy, and progressive intellectual deterioration. In adults, it manifests as movement impairment, talking and eating difficulties, and dementia or behavior changes. 

Redenlab are supporting communication testing and analysis in two multi-domain assessment studies. One, collaborating with Boston Children’s Hospital, Harvard University and The University of Melbourne to measure novel treatment outcomes. The second is a multi-national natural history study across North America and Europe run by CureDRPLA and Ataxia UK.

Related Post

  • Posted on 31 March, 2024
    Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
    • Posted on 25 January, 2024
      MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
      • Posted on 25 January, 2024
        Exposing healthy adults to extended periods of wakefulness is known to induce changes in psychomotor functioning. The effect of fatigue...